MEREO BIOPHARMA GROUP PLC Operating Cash Flow
MEREO BIOPHARMA GROUP PLC (MREO) reported Operating Cash Flow of -$10.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- MEREO BIOPHARMA GROUP PLC net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$6.04M.
- MEREO BIOPHARMA GROUP PLC net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$4.31M.
- MEREO BIOPHARMA GROUP PLC net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$7.68M.
- MEREO BIOPHARMA GROUP PLC net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$7.31M.
- MEREO BIOPHARMA GROUP PLC net cash provided by (used in) operating activities for fiscal 2025 was -$30.97M.
- MEREO BIOPHARMA GROUP PLC net cash provided by (used in) operating activities for fiscal 2024 was -$32.83M.
- MEREO BIOPHARMA GROUP PLC net cash provided by (used in) operating activities for fiscal 2023 was -$21.13M.
- MEREO BIOPHARMA GROUP PLC net cash provided by (used in) operating activities for fiscal 2022 was -$48.82M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$10.36M 10-Q · filed 2026-08-11 | -$18.04M derived: sum of 3 quarters · filed 2026-08-11 | -$25.35M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$4.31M 10-Q · filed 2026-05-12 | -$11.99M derived: sum of 2 quarters · filed 2026-05-12 | -$19.30M derived: sum of 3 quarters · filed 2026-05-12 | -$26.95M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$7.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$14.99M derived: sum of 2 quarters · filed 2026-03-19 | -$22.64M derived: sum of 3 quarters · filed 2026-08-11 | -$30.97M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$7.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$14.96M derived: sum of 2 quarters · filed 2026-08-11 | -$23.29M 10-Q · filed 2025-11-10 | -$32.71M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$7.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$15.98M 10-Q · filed 2026-08-11 | -$25.40M derived: sum of 3 quarters · filed 2026-08-11 | -$32.92M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$8.33M 10-Q · filed 2026-05-12 | -$17.75M derived: sum of 2 quarters · filed 2026-05-12 | -$25.27M derived: sum of 3 quarters · filed 2026-05-12 | -$33.17M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$9.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$16.94M derived: sum of 2 quarters · filed 2026-03-19 | -$24.84M derived: sum of 3 quarters · filed 2026-03-19 | -$32.83M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$7.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$15.42M derived: sum of 2 quarters · filed 2025-11-10 | -$23.41M 10-Q · filed 2025-11-10 | -$30.20M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$7.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$15.89M 10-Q · filed 2025-08-12 | -$22.68M derived: sum of 3 quarters · filed 2025-08-12 | -$20.02M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$7.99M 10-Q · filed 2025-05-13 | -$14.78M derived: sum of 2 quarters · filed 2025-05-13 | -$12.12M derived: sum of 3 quarters · filed 2025-05-13 | -$19.88M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$6.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$4.13M derived: sum of 2 quarters · filed 2025-03-26 | -$11.88M derived: sum of 3 quarters · filed 2025-03-26 | -$21.13M 10-K · filed 2025-03-26 |
| 2023-09-30 | $2.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$5.09M derived: sum of 2 quarters · filed 2024-11-12 | -$14.34M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$7.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$17.00M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$9.25M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$48.82M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |